Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

CONCLUSION: SF3B1 overexpression represents a therapeutic vulnerability in PDAC, as altered splicing can be targeted with Pladienolide-B both in cancer cells and CSCs, paving the way for novel therapies for this lethal cancer.PMID:34857016 | DOI:10.1186/s13046-021-02153-9

Source: Cell Research - December 3, 2021 Category: Cytology Authors: Emilia Alors-Perez Ricardo Bl ázquez-Encinas Sonia Alcal á Cristina Viyuela-Garc ía Sergio Pedraza-Arevalo Vicente Herrero-Aguayo Juan M Jim énez-Vacas Andrea Mafficini Marina E S ánchez-Frías Mar ía T Cano Fernando Abollo-Jim énez Juan A Mar ín- Source Type: research